Recurrence risk of congenital malformations in infants exposed to antiepileptic drugs in utero

Epilepsia

Volumn 54, Issue 1, 2013, Pages 165-171

  Campbell, Ellen ^a   Devenney, Emma ^a   Morrow, Jim ^a   Russell, Aline ^b   Smithson, William Henry ^c   Parsons, Linda ^d   Robertson, Iain ^e   Irwin, Beth ^a   Morrison, Patrick J ^f   Hunt, Stephen ^a   Craig, John ^a  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d BEDFORD HOSPITAL NHS TRUST   (United Kingdom)

^e ROYAL PRESTON HOSPITAL   (United Kingdom)

^f BELFAST CITY HOSPITAL   (United Kingdom)

Author keywords

Antiepileptic drugs; Epilepsy; Pregnancy; Recurrence risk

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; TOPIRAMATE;

ARTICLE; CALCULATION; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DRUG SAFETY; EPILEPSY; FEMALE; FOLLOW UP; GENETIC RISK; HUMAN; INFANT; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRENATAL DRUG EXPOSURE; PRIMIGRAVIDA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RISK ASSESSMENT;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; FEMALE; GREAT BRITAIN; HUMANS; MALE; PARITY; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; REGISTRIES; RISK FACTORS;

EID: 84872082490     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12001     Document Type: Article

References (17)

1. Azzato EM, Chen RA, Wacholder S, Chanock SJ, Klebanoff MA, Caporaso NE,. (2010) Maternal EPHX1 polymorphisms and risk of phenytoin-induced congenital malformations. Pharmacogenet Genomics 20: 58-63.
2. Cunnington MC, Weil JG, Messenheimer JA, Ferber S, Yerby M, Tennis P,. (2011) Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 76: 1817-1823.
3. de Wals P, Mastroiacovo P, Weatherall JAC, Lechat M,. (1984) EUROCAT guide 1. For the registration of congenital anomalies. European Union, Brussels.
4. Dean JC, Moore SJ, Osborne A, Howe J, Turnpenny PD,. (1999) Fetal anticonvulsant syndrome and mutation in the maternal MTHFR gene. Clin Genet 56: 216-220.
5. Dean JCS, Hailey H, Moore SJ, Lloyd DJ, Turnpenny PD, Little J,. (2002) Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 39: 251-259.
6. Hernández-Díaz S, Smith CR, Shen A, Mittendorf R, Hauser WA, Yerby M, Holmes LB,; For the North American AED Pregnancy Registry; North American AED (Antiepileptic Drug) Pregnancy Registry; Scientific Advisory Committee; North American AED Pregnancy Registry. (2012) Comparative safety of antiepileptic drugs during pregnancy. Neurology 78: 1692-1699.
7. Holmes LB, Harvey EA, Coull BA, Huntington KB, Khoshbin S, Hayes AM, Ryan LM,. (2001) The teratogenicity of anticonvulsant drugs. N Engl J Med 344: 1132-1138.
8. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S,. (2011) Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 68: 1275-1281.
9. Hunt S, Russell A, Smithson WH, Parsons L, Robertson I, Waddell R, Irwin B, Morrison PJ, Morrow J, Craig J,; UK Epilepsy and Pregnancy Register. (2008) Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 71: 272-276.
10. Kaneko S, Battino D, Andermann R, Wada K, Kan R, Takeda A, Nakane Y, Ogawa Y, Avanzini G, Fumarola C, Granata T, Molteni F, Pardi G, Minotti L, Canger R, Dansky L, Oguni M, Lopes-Cendas I, Sherwin A, Andermann F, Seni MH, Okada M, Teranishi T,. (1999) Congenital malformations due to anti-epileptic drugs. Epilepsy Res 33: 145-158.
11. Kini U, Lee R, Jones A, Smith S, Ramsden S, Fryer A, Clayton-Smith J,; Liverpool Manchester Neurodevelopmtal Study Group. (2007) Influence of the MTHFR genotype on the rate of malformations following exposure to anti-epileptic drugs in utero. Eur J Med Genet 50: 411-420.
12. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJ, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PE, Smith CT, Vanoli A, Williamson PR,; for the SANAD Study group. (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 369: 1016-1026.
13. Moore SJ, Turnpenny P, Quinn A, Glover S, Lloyd DJ, Montgomery T, Dean JC,. (2000) A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 37: 489-497.
14. Morrow J, Russell A, Guthrie E, Parsons L, Robertson I, Waddell R, Irwin B, McGivern RC, Morrison PJ, Craig J,. (2006) Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77: 193-198.
15. Olafsson E, Hallgrimsson JT, Hauser WA, Ludvigsson P, Gudmundsson G,. (1998) Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 39: 887-892.
16. Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, Vajda F,; EURAP study group. (2011) Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 10: 609-617.
17. Wilson EB,. (1927) Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 22: 209-212.